Technetium Tc-99m DTPA
PreclinicalRadiopharmaceutical
Technetium Tc-99m DTPA is one of 72 small molecule programs targeting Liver Cancer. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Idamycin
PfizerApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Rapamune
PPrism Pharmaceuticals
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Alimta
SShawn Eagle
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Technetium Tc-99m DTPA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Radiopharmaceutical[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Washington